Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; (TSXV: $RLV.V) (OTCQB: $RLLVF) (OTC: $AGTK) (OTCQB: $NUGS) (OTCQB: $HLIX) (CSE: $SLNG.C) (OTC: $EDXC)
Delta, Kelowna, BC, March 3rd, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public announcements.
Relevium Technologies Inc. (TSX.V:RLV) (OTCQB:RLLVF) announced that the Company’s subsidiary, BGX E-Health LLC, has shipped a total of CAD $130,000 worth of generic formulations to its customer, Innova Health Care based in Saudi Arabia.
This represents the first shipment of the initial CAD $1,000,000 purchase order the Company received, as mentioned in a press release dated October 30th 2019.
CEO of Relevium Mr. Useche stated “This first shipment to our international customer presents a new milestone for the Company as it embarks on expanding with global partners around the world for generic formulations and nutraceuticals.” Mr. Useche stated further “Our manufacturing partnerships have enabled us to expand our footprint into international markets such as Saudi Arabia and diversify our global sales channels which stem mainly through online sales”.
The Company anticipates that the shipment for the remainder of the purchase order, valued at approximately CAD $870,000 will be shipped towards the end of March 2020.
Agritek Holdings, Inc. (OTC: AGTK), a fully integrated, active real estate investor and white label provide for popular hemp brands, today announced that the Company will utilize its partnerships with licensed facilities in Florida, Colorado and California to focus on the cultivation and extraction of highly enriched CBG hemp, based on a new medical study that CBG material may have antibiotic potential to fight viral disease in humans.
Recently, McMaster University researchers have identified an antibacterial compound made by cannabis plants that may serve as a lead for new drug development. An interdisciplinary team of McMaster researchers found that the chemical compound, or cannabinoid, called cannabigerol (CBG) is not only antibacterial but also effective in mice against a resilient family of bacteria known as methicillin-resistant Staphylococcus aureus (MRSA). CBG achieved this by targeting the cell membrane of the bacteria. These findings in the laboratory were supported when mice with an MRSA infection were given CBG. The findings were published in the journal American Chemical Society Infectious Diseases.
Agritek Holdings presently has extracted multiple liters of hemp crude oil containing both CBD and CBG hemp material from last year’s farming operations and hemp harvest in Colorado to be used within multiple nutraceutical product lines.
“This new study clearly seems to show evidence and potential for use of CBG cannabinoids as antibiotics which have proven effective in mice against a resilient family of bacteria known as methicillin-resistant Staphylococcus aureus (MRSA). With rapid spread and growing worldwide concern of the coronavirus or COVID-19, perhaps further research on the effectiveness of cannabis’ deeper spectrum can be driven by new and exciting proofs that cannabis can one day help kill superbugs. This realistic approach might be a first important step in our need to improve society’s resistance to disease through a generic means,” stated B. Michael Friedman, CEO of Agritek holdings.
Despite the shock and awe of the traditional pharma community, it is no surprise to see powerful antibacterial effects from CBG in combination with other medications. The effect of the endocannabinoid system helps increase the potency of other antibacterial agents through its major functions. Beyond germs, cannabigerol can slow the spread of viruses throughout the body. CBG can stop the replication of viral infections by inhibiting calcium through several pathways, such as agonizing PPAR-y, a regulator of genetics, tumorigenesis, and many cellular processes. This leads to a widespread anti-inflammatory response that can help orchestrate white blood cells as they attack diseases, like pneumonia. In terms of relieving symptoms, nitric oxide is pneumonia’s weapon of inflammation which cannabis, CBD more than CBG, is an expert at disarming.
Research on this topic is still at an early stage to answer if cannabinoid formulations can truly deal with epidemics as severe as the current form of coronavirus now COVID-19 and originally the Wuhan Virus spreading in Southeast Asia, Europe and now entering the United States and Canada. We do not currently understand the pathogenesis of the disease, in order to develop vaccines or to employ medicinal intervention. Yet, that is the exact point of generic instant treatment, something that cannot be relied upon but can still be delivered with benefits that outweigh the risks. According to current research, CBG is non-intoxicating, mostly non-toxic, and non-sedating so it carries little known risk. The development of cannabinoid formulations might be able to unlock a range of interventions for many outbreaks, bacteria or viral.
Cannabis Strategic Ventures (OTCQB:NUGS), an emerging leader in the U.S. and California cannabis marketplaces, announced robust growth and significant financial improvements for the most recently completed financial period ending Dec. 31, 2019. Revenue for the quarter ending Dec. 31 reached $1.35 million, representing sequential quarterly growth of approximately 91 percent, compared to the previous quarter. Gross margins grew meaningfully while operating efficiencies improved significantly.
“We’re excited to see consistent revenue growth,” commented Simon Yu, CEO of the Company. “In this highly regulated environment, it takes time to scale production. With a considerable portion of the permitting and construction behind us, we are poised for continued growth in the California cannabis marketplace.”
In addition to top-line growth, the Company’s total assets as of the end of the December quarter 2019 was just over $18.7 million from only $2.8 million for the year-ago period. Total current assets now equal approximately 113 percent of current liabilities. Cash and accounts receivables more than doubled as of the end of the nine-month period.
Gross margins for the December 2019 quarter rose to just over 33 percent from 25 percent for the nine month period ending Dec. 31, 2019, and from no gross margin production for the year-ago quarter. The net loss for the December quarter was cut to approximately $1.2 million from over $4.5 million during the September 2019 quarter. Expense ratios improved markedly for the periods ending Dec. 31, 2019.
Mr. Yu continued, “Both the business operations and our financials continue to trend positively. We have been able to substantially grow revenues and improve our gross margins while reducing our operational costs. We feel we are now starting to hit our business stride in the California regulated marketplace, and we look forward to a fruitful 2020.”
This robust growth follows what was already strong growth during the September quarter of 2019. For the nine month period ending December 31, Cannabis Strategic was able to increase revenues by more than $2 million. The Company expects strong revenue growth to continue for the foreseeable future.
Helix Technologies, Inc. (OTCQB:HLIX), the leading provider of critical infrastructure services to the legal cannabis industry, announced today that it has extended two Government Traceability contracts in New York and North Dakota, and will deploy 2 advanced patient registries and upgraded traceability services in Arkansas and New Mexico.
New York and North Dakota have chosen to extend the contract of Biotrack’ss Government Traceability software. Biotrack’s solution maintains a >99.99% uptime record, and best in class digital security features, such as being the only traceability system to deploy in the AWS FEDRAMP GOVCLOUD and to successfully complete a SOC 2 Type II Audit.
In addition, Arkansas and New Mexico also upgraded to the Biotrack advanced patient registry solution, including online application and approval, and mobile patient ID cards.
These innovative solutions have reduced costs, approval time, and hassle for patients. Further, Biotrack is deploying upgrades to the New Mexico system that allows for on-site consumption, and reciprocity between states with medical cannabis programs, improving patient access.
“Delivering cutting edge systems requires fully-secure development capabilities and functionality coupled with the deployment expertise to meet the demands of the industry. In the end, this is about patient access to medication,” said Helix Technologies CEO and Executive Chairman Zachary L. Venegas. “We consider it a tremendous responsibility to ensure patients have access to medication that is safe and tested, while also protecting the integrity of patient data privacy.”
SLANG Worldwide Inc. (CSE: SLNG), a leading global cannabis consumer packaged goods company with a robust portfolio of popular brands, today announced that it has entered into an acquisition agreement dated March 2, 2020 to acquire Cultivate Brands Corp.
Cultivate is a privately-owned company with a portfolio of brands and other intellectual property which are complementary to SLANG's portfolio. Its assets include extraction equipment and other machinery which SLANG intends to use within its network, cash of approximately CAD $4.5 million, and a strategic investment in a company within the supply chain. Cultivate is not currently consuming any cash in its operations.
The Acquisition is expected to further strengthen SLANG's position in Oregon, which the Company has identified as a core market for growth in 2020, due to its status as one of the most mature recreational markets in the United States. SLANG's O.penVAPE Craft RESERVE and Bakked Dabaratus products are strong performers in the state, and the Company recently announced a strategic partnership in Oregon with Cookies, a leading third-party brand that the Company expects to launch in Q2 2020. The Oregon market had retail sales of $810M USD during 2019 and grew 27% year over year as of December 2019 (per BDS Analytics).
The Acquisition is structured as an all-stock transaction in which SLANG will issue a non-material amount of common shares in exchange for all the issued and outstanding shares of Cultivate. The majority of the SLANG Shares issued pursuant to the Acquisition will be subject to a lock-up period with rolling expiration dates.
"We are pleased to execute a deal that contributes brands, IP, equipment, and capital to the already robust SLANG portfolio and balance sheet," said SLANG CEO Peter Miller. "The acquisition of Cultivate will provide a unique opportunity to generate value in several ways including new production assets, supply chain efficiencies and potential new products. This acquisition is consistent with our disciplined growth strategy and our focus on capital efficiency."
"We are pleased to align with a leading cannabis CPG company like SLANG, with its proven capability to develop and grow brands," said Mihalis Belantis, Founder of Cultivate. "This transaction offers significant potential upside to our investors, as well as an opportunity to leverage and commercialize the foundational work we completed during the start-up phase of our business."
The Acquisition will be completed by way of three-cornered amalgamation and is anticipated to close in April 2020. Closing of the Acquisition is subject to the satisfaction or waiver of customary closing conditions, including the receipt of the approval of the shareholders of Cultivate and applicable regulatory approvals.
CBD Unlimited, Inc. (OTC: EDXC), formerly known as Endexx Corporation, a provider of innovative phytonutrient-based food and nutritional products, announced the Company's interview with Stock News Report at the Nasdaq MarketSite is now publicly available for viewing.
On February 14, 2020, CBD Unlimited's Chief Executive Officer and Chairman, Todd Davis, appeared live at the Nasdaq MarketSite with Stock News Now where Davis unveiled the Company's successful product launch, growth within mass retail/pharmacy outlets, international growth, the company's scientific background, testing product efficacy and dosing, acquisition targets, and record revenues. CBD Unlimited believes the Company is well positioned to capitalize on its large retail relationships while boosting sales in 2020.
"It was a pleasure to join Jane King with Stock News Now. Our diligent work in the hemp marketplace is paying off with strong growth, revenues, and near-term completion of acquisitions that will truly position the company as an industry powerhouse," commented Chief Executive Officer and Chairman, Todd Davis.
"All of CBD Unlimited's products are designed with our scientifically-based therapeutics and formulated with natural adaptogen herbs such as ashwagandha, turmeric, ginger, and other viable plant properties that pair well with CBD," continued Davis. "The synergies we have developed between mass retailers, mass pharmacy, and our dedicated partners will continue to help fuel the Company's growth and we look forward to what the rest of 2020 has to hold for the hemp marketplace."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Contact Investorideas.com
800-665-0411
